louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00735540: Clinical Diagnosis of Teenagers Admitted to Pediatric Departments
Official title: The Purpose of This Study is to Analyze the Clinical Characteristics of Teenagers Admitted to Pediatric Departments
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anorexia
Thalassemia
Sickle Cell Anemia
Chronic Renal Failure
Suicide Attempt
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
First posted: 2008-08-15
Enrollment: 1389
Sex: ALL
Minimum age (years): 14
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: About 800 teenagers are admitted each year to the pediatric departments at the Ha'Emek Medical Center. Three principal conditions are the causes of admission: chronic diseases, acute "organic" diseases, and psychiatric diseases including suicide attempts, anorexia, and others.

Brief summary: This study intends to analyze the clinical characteristics of teenagers admitted to pediatric wards due to organic illness and non organic diagnosis, including patients suffering from chronic diseases and comorbidity.

Detailed description: The intention is to summarize the data from year 2000 to 2007 af all the teenagers aged 14 ys to 20 yes admitted to the pediatric wards at the Ha'Emek Medical Center. The demographic and clinical date will be summarized.

Eligibility criteria: Inclusion Criteria: All the patients ages 14 to 20 ys admitted to the pediatric ward.

Exclusion Criteria: No exclusion criteria relevant.

Primary outcomes:
measure: Analyzing the characteristics of Teenagers Admitted to Pediatric Departments
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Afula
country: Israel
facility: Pediatric Dpt B - Ha'Emek Medical Center
Study officials:
affiliation: Pediatric Hematology Unit - Ha'Emek Medical Center - Afula - 18101 - Israel
name: Ariel Koren, MD
role: STUDY_DIRECTOR
affiliation: Pediatric Dpt B - Ha'Emek Medical Center - Afula - Israel
name: Nili Gabay Saar, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Pediatric Psychiatric Unit - Ha'Emek Medical Center- Afula - Israel
name: Ziva Bracha, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02398240: Brentuximab for Newly Diagnosed Hodgkin Disease
Official title: A Pilot Study of Risk Adapted Therapy Utilizing Upfront Brentuximab With Combination Chemotherapy in the Treatment of Children, Adolescents and Young Adults With Newly Diagnosed Hodgkin Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hodgkin Lymphoma
Lead sponsor: New York Medical College
Sponsor class: OTHER
First posted: 2015-03-25
Enrollment: 40
Sex: ALL
Minimum age (years): 1
Maximum age (years): 29
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).


Eligibility criteria: Inclusion Criteria:

* Normal Serum creatinine based on age or creatinine clearance \>60 ml/min/1.73 m2 or an equivalent radioisotope glomerular filtration rate (GFR) as determined by the institutional normal range.
* Direct bilirubin \< 1.5 upper limit of normal (ULN) for age, and SGOT (AST) or SGPT (ALT) \<3 x ULN
* Shortening fraction \>27% by echocardiogram, or
* Ejection fraction of \>50% by radionuclide angiogram or echocardiogram.
* For patients age 1-16 years, Lansky score of ≥60.
* For patients \> 16 years, Karnofsky score of ≥60.
* No prior Hodgkin lymphoma directed therapy is allowed except for emergent mediastinal irradiation (\<1000cGy) for superior vena cava (SVC) syndrome.

Exclusion Criteria:

* Females who are pregnant (positive HCG) or lactating.
* Karnofsky \<60% or Lansky \<60% if less than 16 years of age.
* Age ≤1 year or \>29.99 years of age.

Primary outcomes:
measure: To determine if this combination of chemoimmunotherapy is safe to administer. (Adverse events)
timeFrame: 1 year
measure: To determine the response rate
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Valhalla
country: United States
facility: New York Medical College
state: New York
Study officials:
affiliation: New York Medical College
name: Jessica Hochberg, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hochberg J, Basso J, Shi Q, Klejmont L, Flower A, Bortfeld K, Harrison L, van de Ven C, Moorthy C, Islam H, Gerard P, Voss S, Cairo MS. Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial. J Immunother Cancer. 2022 May;10(5):e004445. doi: 10.1136/jitc-2021-004445.
Clinical trial NCT05641740: Clinical Effects of Radiofrequency in Fibromyalgia
Official title: Clinical Effects of a Single-session of Radiofrequency on Vascular Response and Pain Thresholds in Patients With Fibromyalgia: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fibromyalgia
Keywords: Radiofrequency Therapy
Peripheral blow flow
Core body temperature
Pain
Central sensitization
Peripheral nervous system
Thermography
Lead sponsor: Universidad de Granada
Sponsor class: OTHER
First posted: 2022-12-08
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to analyze the effects of a single-session of Radiofrequency in patients with Fibromyalgia in comparison to a placebo group.

Detailed description: The aim of this study is to analyze the effects of a single-session of Radiofrequency on peripheral vascular blood flow of the skin of the hands and core body temperature in patients with Fibromyalgia in comparison to a placebo group. Also, to study the clinical effects of the intervention on subjective pain perception, pain threshold to pressure and electrical pain threshold and intensity.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Fibromyalgia in accordance with the American College of Rheumatology criteria for classifying Fibromyalgia (2016 revision) by a rheumatologist of the Public Health System of Andalusia (Spain)
* Age from 18 to 70 years
* No other rheumatic diseases
* Absence of regular physical activity
* Limitation of usual activities due to pain on at least 1 day out of the previous 30

Exclusion Criteria:

* Male sex
* Presence of cardiac, renal or hepatic insufficiency;
* Severe physical disability
* Pregnancy or lactation
* Active infections
* Psychiatric illness
* Active tumor.
* Treatment with vasoactive drugs or anticoagulants or a history of drug use
* Skin disorders
* Any other non-pharmacological therapy

Primary outcomes:
measure: Peripheral vascular blood flow
timeFrame: At the end of the radiofrequency session, an average of 20 minutes
Secondary outcomes:
measure: Pain Intensity: Visual Analog Scale
timeFrame: At the end of the radiofrequency session, an average of 20 minutes
measure: Pain Threshold Electric Score
timeFrame: At the end of the radiofrequency session, an average of 20 minutes
measure: Pain Intensity Electric Score
timeFrame: At the end of the radiofrequency session, an average of 20 minutes
measure: Pressure Pain Threshold
timeFrame: At the end of the radiofrequency session, an average of 20 minutes
measure: Core body temperature
timeFrame: At the end of the radiofrequency session, an average of 20 minutes
Other outcomes:
Locations:
city: Granada
country: Spain
facility: University of Granada
state: Andalusia
Study officials:
affiliation: Universidad de Granada
name: Mª Encarnación ME Aguilar Ferrándiz, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00173940: Collection of Blood and Urine Specimens From Volunteers Utilizing Health Examination Services
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Diseases
Hypertension
Diabetes
Obesity
Chronic Renal Failure
Keywords: chronic diseases, such as hypertension, diabetes, obesity, chronic renal failure, and so on
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2005-09-15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT

Brief summary: In summary, the researchers want to construct a longitudinal data bank using voluntary health examination participants. Researchers in the National Taiwan University Hospital (NTUH) campus can utilize these data to clarify the effects of several genetic and environmental factors on various common diseases in Taiwan in the future.


Eligibility criteria: Inclusion Criteria:

* Persons who sign informed consent

Exclusion Criteria:

* Age below 18 years

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: NTUH
Study officials:
affiliation: NTUH
name: Chung-Jen Yen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01180140: Use of Seamguard to Prevent Leak and Bleeding in Gastrointestinal Surgery
Official title: Use of Seamguard to Prevent Digestive Leak and Bleeding on Lineal Stapled Anastomoses: a Prospective Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Leak on Lineal Stapled Anastomoses
Bleeding on Lineal Stapled Anastomoses
Keywords: Seamguard
staple-line reinforcement
leak
bleeding
Lead sponsor: Hospital Universitario de Canarias
Sponsor class: OTHER
Collaborators: name: Unidad mixta de Investigación HUC-ULL
name: University of La Laguna
First posted: 2010-08-11
Enrollment: 113
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determinate the utility of staple-line reinforcement on lineal gastrointestinal anastomoses.

Hypothesis: Seamguard device will decrease the incidence of leak and bleeding in digestive lineal stapled anastomoses.


Eligibility criteria: Inclusion Criteria:

* All patients who will need a lineal stapled anastomoses (colon cancer in cecum, for example)

Exclusion Criteria:

* circular anastomoses
* bariatric surgery

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: La Laguna
country: Spain
facility: Hospital Universitario de Canarias
state: Santa Cruz de Tenerife
Study officials:
References:
Clinical trial NCT00150540: A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.
Official title: A Long Term, Open Label Extension Study of Protocols LAM-IV-301, LAM-IV 303, LAM-IV 307 AND LAM-IV 308.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Kidney Failure, Chronic
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2005-09-08
Enrollment: 93
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety of lanthanum carbonate in patients undergoing dialysis who have received lanthanum carbonate in the previous studies and wish to continue treatment.


Eligibility criteria: Inclusion Criteria:

* Patients who participated in LAM-IV-301, LAM-IV-303, LAM-IV-307 OR LAM-IV-308 and received lanthanum carbonate
* Patients must continue to require treatment with a phosphate binder for hyperphosphatemia
* male or non-pregnant female who agrees to use an effective contraceptive method while on study treatment and for 30 days thereafter

Exclusion Criteria:

* Patients withdrawn from LAM-IV-301, LAM-IV-303 OR LAM-IV-307 prior to randomization
* Patients withdrawn from LAM-IV-301, LAM-IV-303, LAM-IV-307 OR LAM-IV-308 due to adverse events termed "possible" or "related" to study medication
* Pregnant or lactating women

Primary outcomes:
measure: Treatment emergent adverse events
timeFrame: Up to 24 months
Secondary outcomes:
measure: Changes in pre-dialysis serum phosphate levels
timeFrame: Baseline, Months 3, 6, 9, 12, 15, 18, 21, 24.
measure: Control of pre-dialysis serum phosphate levels
timeFrame: Baseline, Months 3, 6, 9, 12, 15, 18, 21, 24.
measure: Plasma lanthanum levels
timeFrame: Baseline, Months 3, 6, 9, 12, 15, 18, 21, 24.
Other outcomes:
Locations:
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT06294340: Noise, Oxidative Stress and Cardiovascular System
Official title: Noise, Oxidative Stress and Cardiovascular System
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Noise; Adverse Effect
Noise Exposure
Lead sponsor: University of Belgrade
Sponsor class: OTHER
First posted: 2024-03-05
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All persons who visit the Nutrition Counselling Unit of the Institute of Hygiene and Medical Ecology, located at the Faculty of Medicine, University of Belgrade will be eligible to participate in the study. The study population will include 75 participants with normal weight and 75 overweight/obese participants who meet the inclusion criteria for the survey. Participants will be informed of the protocol and sign an informed consent form.

Brief summary: Environmental noise represents a health problem for at least one in five citizens of the European Union. Noise exposure leads to the development of arterial hypertension, myocardial infarction, stroke, and obesity. Given the limited information on noise exposure and noise effects on humans in the Republic of Serbia, the overall objective of NOXYCARD is to collect environmental noise levels data; to identify long-term and short-term noise effects on the cardiovascular system; and to evaluate the levels of blood stress hormones, oxidative stress, and inflammation in individuals with normal body weight and individuals with obesity.


Eligibility criteria: Inclusion Criteria:

* age 18-65
* both genders
* good self-reported health

Exclusion Criteria:

* diabetes mellitus
* arterial hypertension or other cardiovascular diseases
* kidney diseases
* pregnancy
* malignant diseases
* mental diseases

Primary outcomes:
measure: Systolic blood pressure
timeFrame: 10, 40, and 50 minutes
measure: Concentration of stress hormone
timeFrame: 10, 40, and 50 minutes
Secondary outcomes:
measure: Diastolic blood pressure
timeFrame: 10, 40, and 50 minutes
measure: Concentration of inflammation parameters
timeFrame: 10, 40, and 50 minutes
Other outcomes:
Locations:
city: Belgrade
country: Serbia
facility: Faculty of Medicine, University of Belgrade
state: Beograd
Study officials:
affiliation: Faculty of Medicine, University of Belgrade
name: Katarina Paunovic, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Paunovic K, Jakovljevic B, Stojanov V. The timeline of blood pressure changes and hemodynamic responses during an experimental noise exposure. Environ Res. 2018 May;163:249-262. doi: 10.1016/j.envres.2018.01.048. Epub 2018 Feb 22.
citation: Paunovic K, Stojanov V, Jakovljevic B, Belojevic G. Thoracic bioelectrical impedance assessment of the hemodynamic reactions to recorded road-traffic noise in young adults. Environ Res. 2014 Feb;129:52-8. doi: 10.1016/j.envres.2014.01.001. Epub 2014 Jan 25.
Clinical trial NCT01464840: The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery
Official title: The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometritis
Keywords: Pregnancy
Cesarean section
Antibiotic
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2011-11-04
Enrollment: 30
Sex: FEMALE
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Pregnant women 19 years and older undergoing scheduled cesearean sections

Brief summary: PKAZ is a single institution study designed to evaluate the optimal dosing parameters for azithromycin for pre-surgical cesarean prophylaxis.

Hypothesis: Pre-operative administration of azithromycin results in maternal and neonatal tissue concentrations that adequately treat microbes commonly involved in post-cesarean infections.


Eligibility criteria: Inclusion Criteria:

* Women 19 years and older
* Term (37 weeks and greater)
* Singleton gestation
* Scheduled cesarean section
* Non-laboring
* Intact membranes

Exclusion Criteria:

* \< 19 years of age
* Preterm (\< 37 weeks)
* Multifetal gestation
* Laboring or ruptured membranes
* Known fetal anomaly
* Oligo- or polyhydramnios
* Macrolide allergy
* Macrolide exposure within 2 weeks
* Medical co-morbidities
* Hepatic or renal impairment
* Taking medications that prolong the QT interval
* Currently taking nelfinavir, efavirenz, or flucanozole
* Structural heart defects or arrythmia

Primary outcomes:
measure: Number of Patients in Each Group That Attain an Adequate Azithromycin Concentration
timeFrame: 48 hours after delivery
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
Study officials:
affiliation: University of Alabama at Birmingham
name: Amelia L Sutton, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03596840: Community-based Microalbuminuria Screening in Patients With Hypertension
Official title: Effectiveness of Different Antihypertensive Medications on Urine Albumin-to-Creatinine Ratio (UACR) in Community Hypertensive Patients With Microalbuminuria
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hypertension
Microalbuminuria
Keywords: Hypertension
Microalbuminuria
Effectiveness
Antihypertensive medications
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
First posted: 2018-07-24
Enrollment: 3000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Community Hypertensive Patients With Microalbuminuria

Brief summary: This study evaluates the effectiveness of different anti-hypertensive drugs on patients with hypertension and microalbuminuria.

Detailed description: This is a a real world registry study. All patients with hypertension in community hospitals in China will be eligible . Patient demographics, medical history, clinical characteristics, physical examination, laboratory tests (including UCAR, blood routine, urine routine, blood biochemistry, and ECG), antihypertensive drugs (including: ACEI/ ARB, thiazide diuretics, CCB, beta-blockers, alpha-blockers, and other antihypertensive drugs used in real-life clinical practice in other communities.) will be recorded. All patients are anticipated to be followed up for 12-month. Effectiveness of different antihypertensive medications on Urine Albumin-to-Creatinine Ratio (UACR) will be evaluted.

Eligibility criteria: Inclusion Criteria:

* Patients with essential hypertension;
* Urinary albumin/creatinine ratio in random urine samples is 30-300 mg/g
* Age \>=18
* Understand and sign informed consent

Exclusion Criteria:

* This is a real-world registry study and does not set exclusion criteria

Primary outcomes:
measure: Urine Albumin-to-Creatinine Ratio (UCAR)
timeFrame: 12 months
Secondary outcomes:
measure: Combined endpoints: re-admission, cardiovascular events, and all-cause mortality
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03109340: Efficacy of ECE PEDO (Equipment for Clever Exercise) on Abdominal Obesity
Official title: Efficacy of Moderate Intensity Walking Provided Feedback by ECE PEDO on Abdominal Fat in Women With Overweight and Obesity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity, Abdominal
Physical Activity
Keywords: abdominal obesity
walking
aerobic exercise
Lead sponsor: Pamukkale University
Sponsor class: OTHER
First posted: 2017-04-12
Enrollment: 65
Sex: FEMALE
Minimum age (years): 26
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Women with overweight and obesity were assigned to two groups: supervised treadmill walking (Group I) or walking with ECE PEDO (Group II).
Primary purpose: TREATMENT

Brief summary: Objective: To show the effectiveness of walking with ECE PEDO (Equipment for Clever Exercise) comparing supervised treadmill walking corresponding moderate aerobic exercise intensity on abdominal obesity and cardiorespiratory capacity.

Detailed description: Objective: To show the effectiveness of walking with ECE PEDO (Equipment for Clever Exercise) comparing supervised treadmill walking corresponding moderate aerobic exercise intensity on abdominal obesity and cardiorespiratory capacity.

Methods: Twenty-eight women with overweight and obesity were assigned to two groups: supervised treadmill walking (Group I,n=14) or walking with ECE PEDO (Group II,n=14). Target heart rate(HR) corresponding to values of 50-70% VO2max were determined by the submaximal treadmill test. Group 1 was instructed walking at their target HR on a treadmill. The number of steps taken in a minute corresponding to target HR was determined by a criterion pedometer and group 2 was instructed walking in these step range recorded to ECE PEDO giving audible feedback. Before and after a 12-week exercise program, participants were evaluated by BMI and waist circumference(WC); ultrasonographic visceral fat thickness(VFT) and ergospirometric VO2max.

Eligibility criteria: Inclusion Criteria:

* Eligible participants who meet the criteria for inclusion were women with overweight weight or obesity and were 26-60 years old with a BMI (in kg/m2) from 27.1 to 39.6 and, waist circumference \> 80 cm.

Exclusion Criteria:

* The exclusion criteria were BMI values less than 24.9 and higher than 40, presence of a atherosclerotic heart disease, musculoskeletal or systemic diseases contradicting the exercise, a neurological or psychiatric disease affecting cooperation and cognitive function, and participation in a calorie restricted diets.

Primary outcomes:
measure: Change from baseline in abdominal visceral fat thickness (VFT) at week 12.
timeFrame: Week 12.
measure: Change from baseline in body mass index (BMI) at week 12.
timeFrame: Week 12.
measure: Change from baseline in waist circumference at week 12.
timeFrame: Week 12.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Pamukkale
name: Fusun Ardic, Prof.
role: STUDY_CHAIR
References: